2LB Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Iovance Biotherapeutics Inc

Watchlist Manager

Watchlist

Price: 3.735 EUR 8.42%

Market Cap: €1B

I	Iovance Biotherapeutics Inc SWB:2LB	US
	Informatica Inc NYSE:INFA	US
	Shofu Inc F:69W	JP
S	Suzano SA SWB:SPXB	BR
L	Linde PLC F:LIN	UK

Profitability Summary

Iovance Biotherapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

37%

Negative 3Y Average Gross Margin

-256%

Gross Margin is Increasing

-754% > 37%

Negative Operating Margin

-127%

Negative 3Y Average Operating Margin

-25.626%

Operating Margin is Increasing

-178.496% > -127%

Negative Net Margin

-124%

Negative 3Y Average Net Margin

-24.935%

Net Margin is Increasing

-174.517% > -124%

Negative Free Cash Flow Margin

-107%

Negative 3Y Average Free Cash Flow Margin

-21.417%

Free Cash Flow Margin is Increasing

-147.783% > -107%

Negative ROE

-48%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-96%

ROIC is Increasing

-133% > -63%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.